Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
DNA polymerase gamma is the sole DNA polymerase responsible for replication and repair of mitochondrial DNA in human cells. It functions as a heterotrimeric holoenzyme composed of a single catalytic subunit (encoded by the POLG gene) and a dimer of accessory subunits; the catalytic subunit has both polymerase (replicative) and 3’-5’ exonuclease (proofreading) activities. Proper function of this enzyme is essential for maintenance of mitochondrial genome stability, energy metabolism, and cellular homeostasis. Mutations in POLG or inhibition by certain antiviral drugs (notably NRTIs for HIV) can result in mitochondrial DNA depletion or multiple deletions, contributing to a range of mitochondrial diseases with neurological, hepatic, muscular, or gastrointestinal manifestations. This enzyme is therefore both a key biomolecule for normal mitochondrial function and a clinically important drug target and toxicity mediator.
Inhibition of polymerase activity via incorporation of nucleoside analogs, Competitive inhibition, Chain termination during replication
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on DNA polymerase gamma, catalytic subunit (human) (POLG).